Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
Jordi Bruix(Hospital Clínic de Barcelona), Tadatoshi Takayama(Nihon University), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Gar-Yang Chau(Taipei Veterans General Hospital), Jiamei Yang(Second Military Medical University), Masatoshi Kudo(Kindai University), Jianqiang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Ronnie T.P. Poon(Queen Mary Hospital), Kwang‐Hyub Han(Severance Hospital), Won Young Tak(Kyungpook National University), Han Chu Lee(Asan Medical Center), Tianqiang Song(Tianjin Medical University), Sasan Roayaie(Lenox Hill Hospital), Luigi Bolondi(University of Bologna), Kwan Sik Lee(Gangnam Severance Hospital), Masatoshi Makuuchi(Bunkyo University), Fabrício Henrique Pereira De Souza, Marie‐Aude Le Berre(Bayer (France)), Gerold Meinhardt(Bayer (United States)), Josep M. Llovet(Mount Sinai Medical Center)
Cited by 1,099
Abstract
Related Papers
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al.|New England Journal of Medicine|2008|12.9k